Motor Neurone Diseases Pipeline Examined in Insightful Global Markets Direct Report Available at MarketPublishers.com Business Wire LONDON -- May 21, 2013 Motor neurone diseases (MND) results in a progressive paralysis which is finally stopped by the patient’s death. They are rare - their annual incidence is approximately 2.1 cases per 100,000 population. More common in people aged over 50, the illnesses can be diagnosed at any age. Amyotrophic lateral sclerosis (ALS) is the most common type of MDN. Currently, the only drug used for the direct treatment of MND is Riluzole. However, it does not help the patients to recover, but extend their survival rates by around 3 months. Other medications used to treat MND include: hyoscine, tizanidine, oral morphine, etc. Market research report “Motor Neurone Diseases – Pipeline Review, H1 2013” developed by Global Markets Direct offers a detailed review of worldwide therapeutic scenario for motor neurone diseases. The study contains in-depth overview of the diseases, data on products under development and top players engaged in the therapeutic development for MND. The report provides information on main discontinued pipeline projects, the most recent news and activities relating to the field. Information on pipeline projects on the basis of combined therapeutics and monotherapy is available in the study too. Report Details: Title: Motor Neurone Diseases – Pipeline Review, H1 2013 Published: April 30, 2013 Pages: 37 Price: US$ 2,000.00 http://marketpublishers.com/report/healthcare/therapy/motor-neurone-diseases-pipeline-review-h1-2013.html Report Contents: Introduction Global Markets Direct Report Coverage Motor Neurone Diseases Overview Therapeutics Development An Overview of Pipeline Products for Motor Neurone Diseases Motor Neurone Diseases Therapeutics under Development by Companies Motor Neurone Diseases Therapeutics under Investigation by Universities/Institutes Early Clinical Stage Products Comparative Analysis Discovery and Pre-Clinical Stage Products Comparative Analysis Motor Neurone Diseases Therapeutics – Products under Development by Companies Motor Neurone Diseases Therapeutics – Products under Investigation by Universities/Institutes Companies Involved in Motor Neurone Diseases Therapeutics Development Oxford BioMedica plc NeuroSearch A/S Omeros Corporation Motor Neurone Diseases – Therapeutics Assessment Assessment by Monotherapy Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles MoNuDin - Drug Profile Product Description Mechanism of Action R&D Progress NRP-2945 - Drug Profile Product Description Mechanism of Action R&D Progress GPR139 Antagonist - Drug Profile Product Description Mechanism of Action R&D Progress … More market research reports by Global Markets Direct can be found at http://marketpublishers.com/members/globalmarketsdir/info.html Contact: The Market Publishers, Ltd. Tanya Rezler Tel: +44 208 144 6009 Fax: +44 207 900 3970 firstname.lastname@example.org MarketPublishers.com
Motor Neurone Diseases Pipeline Examined in Insightful Global Markets Direct Report Available at MarketPublishers.com
Press spacebar to pause and continue. Press esc to stop.